Clinical Trials Logo

Filter by:
NCT ID: NCT04026659 Completed - Cancer Clinical Trials

The Feasibility of Implementing an Exercise Programme for Deconditioned Cancer Survivors

FIXCAS
Start date: September 25, 2019
Phase: N/A
Study type: Interventional

As both the number of cancer survivors and the length of survival time are increasing, long-term health issues related to cancer and its treatment are becoming more prevalent. Research suggests that exercise can mitigate a number of negative health consequences in cancer survivors and improve physical function and quality of life. Multi-modal exercise interventions have been proposed as a cornerstone for survivorship care. However, studies evaluating exercise programmes within the Irish population are lacking. The aim of the study is to evaluate the introduction, implementation and acceptability of a multi-modal exercise rehabilitation programme for deconditioned cancer survivors in a real-world, standard practice setting.

NCT ID: NCT04013945 Completed - Physiology, Skin Clinical Trials

Study to Investigate the Effect of Superba Boost on the Skin.

Start date: March 13, 2019
Phase: N/A
Study type: Interventional

Study to determine the effect of 12 weeks daily consumption of Superba Boost as compared to placebo on changes in Trans-Epidermal Water-Loss (TEWL).

NCT ID: NCT04004013 Completed - Clinical trials for Osteopenia, Generalized

Evaluate the Effect of Lifenol in Improving Bone Status in Postmenopausal Osteopenic Women

Start date: August 1, 2019
Phase: N/A
Study type: Interventional

A Randomised, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Effect of Lifenol® in Improving Bone Status in Postmenopausal Osteopenic Women. 100 postmenopausal women will be enrolled to investigate the effect of a 12 month supplementation with Lifenol® on bone density DXA parameters and plasma bone biomarkers.

NCT ID: NCT04003597 Completed - Clinical trials for Elevated Blood Pressure

'Low-salt' Bread as a Means of Reducing Dietary Salt and Lowering Blood Pressure

Saltbreads
Start date: January 3, 2008
Phase: N/A
Study type: Interventional

In the context of public health, reformulation of bread in terms of salt content remains an important measure to help achieve a reduction in salt intake in the population. Therefore, the aim of this study was to examine, using a 5-week cross-over design, food-based intervention trial, the potential for inclusion of 'low-salt' bread as part of a pragmatic reduced-salt diet on blood pressure (BP) in adults with slightly to moderately elevated BP. The study consisted of a randomized crossover trial of the effect of reduced-salt intake or usual-salt intake for 5 weeks on BP (as the primary outcome) in adults with slightly to moderately elevated BP (seated office systolic BP >120 and <160 mmHg or a diastolic BP >80 and <95 mmHg; identified by a pre-screening phase). Subjects were randomly assigned to the reduced-salt diet or their usual-salt diet (control) for 5 weeks, followed by crossover to the alternative dietary regimen for a further 5 weeks. Subjects randomized to start on the reduced-salt diet were asked to restrict their consumption of dietary salt using a combination of pragmatic dietary advice as well as the replacement of bread and a limited number of other foods with equivalent foods which had lower salt content; these were provided to the participants. At the beginning of the salt restriction period, a research nutritionist provided the subjects with a list of the common salt-containing food and were asked to limit the consumption of such, as feasible. The subjects received in-house prepared 'low-salt (<0.3 g/100 g)' brown or white sliced pan bread as well as no-salt margarine/butter, and were given luncheon meats with no added salt, if desired (optional); these were supplied regularly by the research staff. Subjects commencing the trial on the control diet were allowed to follow their usual diet but were asked to consume an in-house produced brown or white sliced pan bread equivalent in composition to the low-salt version but with its more typical salt content (1.2 g/100 g). Participants met the research staff weekly to receive breads and no-salt margarine/butter as well as luncheon meats (where applicable), and at these meetings the staff promoted compliance with the intervention and encouraged completion of the study protocol. BP and other assessments were made at baseline and at the end of week 5 and week 10.

NCT ID: NCT03988660 Completed - Appendicitis Clinical Trials

The Circulating Fibrocyte - a Novel and Accurate Biomarker in Diagnosing Acute Appendicitis in Adults

Start date: June 10, 2015
Phase:
Study type: Observational [Patient Registry]

Accurate diagnostic biomarkers for acute appendicitis (AA) are lacking. Circulating fibrocytes (CFs) are increased in inflammatory states. It is not known whether they are altered in appendicitis. This study aimed to assess if CF altered in AA, and compared their diagnostic accuracy with white cell count (WCC), C-reactive protein (CRP), neutrophils, lymphocytes, neutrophils-lymphocytes ratio (NLR), monocytes, basophils and eosinophils in diagnosis of AA in patients presenting with right iliac fossa pain (RIFP). 95 consecutive adults were recruited in a cohort based prospective study at University Hospital Limerick, 15 were healthy individuals and 80 were patients with RIFP. Peripheral venous samples were obtained at presentation. Clinical, biochemical and histo-pathological parameters were recorded. CF levels were determined by dual-staining for CD45 and Col-1 using FACS and correlated with histopathological diagnoses. P<0.05 was taken as significant. The study hypothesis is that in patients with suspected appendicitis, CF levels may improve the diagnostics, reduce unnecessary radiation and negative appendicectomy rates.

NCT ID: NCT03980314 Completed - Melanoma Clinical Trials

A Study to Compare Nivolumab Drug Product Process D to Nivolumab Drug Product Process C in Participants With Stage IIIa/b/c/d or Stage IV Melanoma After Complete Resection

Start date: June 24, 2019
Phase: Phase 1
Study type: Interventional

The purpose of this study is to compare the drug levels, immunogenicity and safety of Nivolumab Process D to Nivolumab Process C after complete resection of stage IIIa/b/c/d or stage IV melanoma.

NCT ID: NCT03979118 Completed - Advanced Cancer Clinical Trials

Exercise Prescription in Patients With Bone Metastases

Ex-Met
Start date: October 15, 2019
Phase:
Study type: Observational

Cancer which has spread to the bone, causing bone metastases (bone tumours) can weaken bone health and increase risk of fractures (breaks). Consequently, patients can be unsure whether to exercise and health professionals can be unsure what exercise advice is suitable. Despite this, it is well known that exercise improves quality-of-life for patients with bone metastases and therefore it is important that exercise is prescribed to these patients. This study aims to increase understanding of the link between daily exercise and risk of fracture in patients with bone metastases.

NCT ID: NCT03970564 Completed - Clinical trials for Lung Cancer Metastatic

Neck Ultrasound by Respiratory Physicians in Patients With Lung Cancer

Start date: October 21, 2016
Phase:
Study type: Observational

This is a study of routine neck ultrasound performed by respiratory physicians in patients with mediastinal lymphadenopathy and suspected lung cancer

NCT ID: NCT03951103 Completed - Clinical trials for Hemophilia A With Inhibitor

rFVIIIFc (Elocta®) ITI Chart Review in Patients With Haemophilia A

Start date: November 7, 2018
Phase:
Study type: Observational

A chart review study of patients with haemophilia A with inhibitors treated with rFVIIIFc (Elocta®) for immune tolerance induction.

NCT ID: NCT03939767 Completed - Clinical trials for Wet Age-related Macular Degeneration

Assessment of Proactive Treatments in Patients With Wet Age-related Macular Degeneration (wAMD) Which Have Never Undergone Treatment of This Particular Disease

XTEND
Start date: May 12, 2019
Phase:
Study type: Observational

In this observational study researchers want to learn more about changes in visual acuity (clarity of vision) with proactive flexible treatments over time in patients suffering from wet age-related macular degeneration (wAMD) after decision to treat with Aflibercept (Eylea) was made. Wet AMD is an eye disease that progressively destroys the macula, the central portion of the retina, impairing central vision.